The Company is pleased to announce that development is underway based on an agreement launched in June 2021 between the Company Unitaid and the Clinton Health Access Initiative (CHAI) to accelerate the development commercialization and registration of the best-in-class second- and third-line HIV treatment darunavir boosted with ritonavir (DRV/r) for children.
Despite being available in high-income countries for over a 15-year period a generic fixed-dose combination pediatric version of DRV/r is still not available. Through this agreement Unitaid and CHAI are working with the Company to finally address this critical need and ensure CLHIV (Children Living with HIV/AIDS) have access to high-quality second- and third-line HIV treatment.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
